Editorial: Interplay between epigenetic modifiers and transcription factors in driving cancer progression

Yongyong Yang; Annalisa Di Ruscio; Satoshi Inoue; Guocan Wang; Shuai Gao

doi:10.3389/fonc.2023.1211537

Editorial: Interplay between epigenetic modifiers and transcription factors in driving cancer progression

Front Oncol. 2023 Jun 19:13:1211537. doi: 10.3389/fonc.2023.1211537. eCollection 2023.

Authors

Yongyong Yang¹, Annalisa Di Ruscio^{2

3}, Satoshi Inoue^{4

5}, Guocan Wang⁶, Shuai Gao^{7

8}

Affiliations

¹ Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
² Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA, United States.
³ Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
⁴ Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
⁵ Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan.
⁶ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
⁷ Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, United States.
⁸ Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY, United States.

No abstract available

Keywords: drug-resistance; epigenetic modulators; gene transcription; liquid-like phase separation; prostate cancer; reprogramming; super-enhancer; transcription factors.

Publication types

Editorial

Grants and funding

R01 DK136116/DK/NIDDK NIH HHS/United States